Laura Rassenti
Overview
Explore the profile of Laura Rassenti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
8277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
La Ferlita A, Nigita G, Tsyba L, Palamarchuk A, Alaimo S, Pulvirenti A, et al.
Proc Natl Acad Sci U S A
. 2023 Oct;
120(44):e2307593120.
PMID: 37871223
Chronic lymphocytic leukemia (CLL) is one of the most diagnosed forms of leukemia worldwide and it is usually classified into two forms: indolent and aggressive. These two forms are characterized...
2.
Gutierrez C, AlKhafaji A, Brenner E, Johnson K, Gohil S, Lin Z, et al.
Nat Cancer
. 2021 Dec;
2(7):758-772.
PMID: 34939038
Lineage-tracing methods have enabled characterization of clonal dynamics in complex populations, but generally lack the ability to integrate genomic, epigenomic and transcriptomic measurements with live-cell manipulation of specific clones of...
3.
Kretzmer H, Biran A, Purroy N, Lemvigh C, Clement K, Gruber M, et al.
Blood Cancer Discov
. 2021 Feb;
2(1):54-69.
PMID: 33604581
Most human cancers converge to a deregulated methylome with reduced global levels and elevated methylation at select CpG islands. To investigate the emergence and dynamics of the cancer methylome, we...
4.
Walker J, Hing Z, Harrington B, Baumhardt J, Ozer H, Lehman A, et al.
J Hematol Oncol
. 2021 Jan;
14(1):17.
PMID: 33451349
Background: Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point...
5.
Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, et al.
Nature
. 2019 May;
570(7762):474-479.
PMID: 31142838
How the genomic features of a patient's cancer relate to individual disease kinetics remains poorly understood. Here we used the indolent growth dynamics of chronic lymphocytic leukaemia (CLL) to analyse...
6.
Hasan M, Rassenti L, Widhopf 2nd G, Yu J, Kipps T
Leukemia
. 2018 Dec;
33(3):653-661.
PMID: 30568170
Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines. Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We discovered...
7.
Manouchehri S, Ibsen S, Wright J, Rassenti L, Ghia E, Widhopf 2nd G, et al.
Int J Hematol Oncol
. 2018 Oct;
5(1):27-35.
PMID: 30302201
Aim: Circulating cell free (ccf) DNA contains information about mutations affecting chronic lymphocytic leukemia (CLL). The complexity of isolating DNA from plasma inhibits the development of point-of-care diagnostics. Here, we...
8.
Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda W, Keating M, et al.
Br J Haematol
. 2016 Oct;
180(4):597-600.
PMID: 27766619
No abstract available.
9.
Lampson B, Kasar S, Matos T, Morgan E, Rassenti L, Davids M, et al.
Blood
. 2016 Jun;
128(2):195-203.
PMID: 27247136
Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as front-line therapy, we enrolled 24 subjects in...
10.
Oakes C, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert A, et al.
Nat Genet
. 2016 Jan;
48(3):253-64.
PMID: 26780610
Charting differences between tumors and normal tissue is a mainstay of cancer research. However, clonal tumor expansion from complex normal tissue architectures potentially obscures cancer-specific events, including divergent epigenetic patterns....